Kyverna Therapeutics, Inc. KYTX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s total liabilities?
- Kyverna Therapeutics, Inc. (KYTX) reported total liabilities of $61.44M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s total liabilities changed year-over-year?
- Kyverna Therapeutics, Inc.'s total liabilities increased by 67.7% year-over-year, from $36.65M to $61.44M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s total liabilities?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s total liabilities has grown at a 53.8% compound annual growth rate (CAGR), from $26.02M to $61.55M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.